Intravenous recombinant tissue plas...

Intravenous recombinant tissue plasminogen activator (rtPA) is believed to provide effective thrombolysis for ischemic misfortune if given within three hours of symptom assault More recent studies have raised the possibility of a longer therapeutic window, if it were not that the benefits of starting rtPA more than three hours after the clinical assault of stroke remain unclear. A meta-analysis of all available trials aimed to establish whether time is a critical factor in thrombolytic therapy for ischemic stroke

The researchers examined data from six major clinical trials, which included 99 percent of all patients in randomized controll clinical trials of intravenous rtPA in patients with acute ischemic attack All trials had similar inclusion criteria based onward neurologic deficit and computed tomography. The time allowed to start treatment varied between trials from 90 to 360 minutes. near trials had age limitations for participants, and others exclud patients who were rapidly improving or had barely minor symptoms.

The dose of rtPA used varied from 09 to 11 mg by means of kg, but all studies gave a 10 percent bolus during the first minute, followed according to an infusion lasting one hour. The trials also differed in output measures, and the duration of follow-up ranged from 30 to 90 days.

The meta-analysis included 2775 patients who were randomized to receive rtPA thrombolysis or placebo. The patients were predominantly white (85 percent) and the median age was 68 years. The median score forward the National Institutes of Health hit Scale (NIHSS) was 11. The median onset-to-treatment time was 243 minutes, and 67 percent of patients were treated for longer than three hours after symptom charge The researchers adjusted for age, vital fluid glucose level, NIHSS score, diastolic life-current pressure on admission, and previous hypertension.

At three month 14 percent of the patients had died or had the worst assigned score. An additional 255 percent were harshly disabled. The odds of a favorable issue at three months were related to quick treatment. Patients treated within 90 minutes had remainings of a good three-month consequence of 2.8, com-pared with 16 in those treated 91 to 180 minutes after symptom onset; 14 in those treated 181 to 270 minutes after symptom onset; and 12 in those treated 271 to 360 minutes after attack Hemorrhage, which occurred in 59 percent of treated patients compared with 11 percent of regulate patients, was not related to timing of rtPA treatment.

The authors judge that early administration of rtPA is associated with greater chance of pious outcomes, but that the window for potential benefit stretch outs beyond the suggested limit of three hours from storming of symptoms.

Association of issue with early stroke treatment: loched analysis of ATLANTIS, ECASS, and NINDS rtPA hardship trials. The ATLANTIS, ECASS, and NINDS rtPA meditation Group Investigators. Lancet March 6 2004;363:768-74

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group